References
1. Cuzick J, Sestak I, Forbes JF, et al. Anastrozole for prevention of
breast cancer in high-risk postmenopausal women (IBIS-II): an
international, double-blind, randomised placebo-controlled trial.The Lancet. 2014;383(9922):1041-1048.
2. Lancet EBCTCGJT. Aromatase inhibitors versus tamoxifen in early
breast cancer: patient-level meta-analysis of the randomised trials.
2015;386(10001):1341-1352.
3. Mincey BA, Duh MS, Thomas SK, et al. Risk of cancer
treatment—associated bone loss and fractures among women with breast
cancer receiving aromatase inhibitors. Clinical breast cancer.2006;7(2):127-132.
4. Sabel MS. Chapter 17 - Principles of Adjuvant Hormonal Therapy. In:
Sabel MS, ed. Essentials of Breast Surgery. Mosby; 2009:267-278.
5. The A. Anastrozole alone or in combination with tamoxifen versus
tamoxifen alone for adjuvant treatment of postmenopausal women with
early breast cancer: first results of the ATAC randomised trial.The Lancet. 2002;359(9324):2131-2139.
6. Crew KD, Greenlee H, Capodice J, et al. Prevalence of joint symptoms
in postmenopausal women taking aromatase inhibitors for early-stage
breast cancer. Journal of Clinical Oncology.2007;25(25):3877-3883.
7. Bender CM, Sereika SM, Brufsky AM, et al. Memory impairments with
adjuvant anastrozole versus tamoxifen in women with early-stage breast
cancer. Menopause (New York, NY). 2007;14(6):995.
8. Breckenridge LM, Bruns GL, Todd BL, Feuerstein M. Cognitive
limitations associated with tamoxifen and aromatase inhibitors in
employed breast cancer survivors. Psycho‐Oncology.2012;21(1):43-53.
9. So WK, Marsh G, Ling W, et al. The symptom cluster of fatigue, pain,
anxiety, and depression and the effect on the quality of life of women
receiving treatment for breast cancer: a multicenter study. Paper
presented at: Oncology nursing forum2009.
10. Cella D, Fallowfield L, Barker P, Cuzick J, Locker G, Howell A.
Quality of life of postmenopausal women in the ATAC (“Arimidex”,
tamoxifen, alone or in combination) trial after completion of 5 years’
adjuvant treatment for early breast cancer. Breast cancer research
and treatment. 2006;100(3):273-284.
11. Baglia ML, Lin IH, Cartmel B, et al. Endocrine‐related quality of
life in a randomized trial of exercise on aromatase inhibitor‐induced
arthralgias in breast cancer survivors. Cancer. 2019.
12. Snaith RP. The hospital anxiety and depression scale. Health
and quality of life outcomes. 2003;1(1):1-4.
13. Harris SR, Schmitz KH, Campbell KL, McNeely ML. Clinical practice
guidelines for breast cancer rehabilitation: syntheses of guideline
recommendations and qualitative appraisals. Cancer.2012;118(S8):2312-2324.
14. Reyes-Gibby CC, Anderson KO, Morrow PK, Shete S, Hassan S.
Depressive symptoms and health-related quality of life in breast cancer
survivors. Journal of women’s health. 2012;21(3):311-318.
15. Holland JC, Bultz BD. The NCCN guideline for distress management: a
case for making distress the sixth vital sign. Journal of the
National Comprehensive Cancer Network. 2007;5(1):3-7.
16. Jacobson E. Progressive muscle relaxation. Interview
Behaviour” Journal of Abnormal Psy-University of Chicago Piess, Chicago
chology. 1938;75(1):18.
17. Bell JA, Saltikov JB. Mitchell’s relaxation technique: Is it
effective? Physiotherapy. 2000;86(9):473-478.
18. Bernstein DA, CARLSON CR, SCHMIDT JE. Progressive relaxation.Stress Management. 1973:88.
19. Otman A, Köse N. Egzersiz tedavisinde temel prensipler ve yöntemler.Meteksan AŞ. 2006:21-51.
20. Kurt B, Kapucu S. The effect of relaxation exercises on symptom
severity in patients with breast cancer undergoing adjuvant
chemotherapy: An open label non-randomized controlled clinical trial.European Journal of Integrative Medicine. 2018;22:54-61.
21. Hojan K, Molińska-Glura M, Milecki P. Physical activity and body
composition, body physique, and quality of life in premenopausal breast
cancer patients during endocrine therapy–a feasibility study.Acta Oncologica. 2013;52(2):319-326.
22. Lu G, Zheng J, Zhang L. The effect of exercise on aromatase
inhibitor-induced musculoskeletal symptoms in breast cancer survivors: a
systematic review and meta-analysis. Supportive Care in Cancer.2020;28(4):1587-1596.
23. Galantino ML, Desai K, Greene L, DeMichele A, Stricker CT, Mao
JJJICT. Impact of yoga on functional outcomes in breast cancer survivors
with aromatase inhibitor–associated arthralgias. 2012;11(4):313-320.
24. Dicle A, Karayurt Ö, Dirimese EJPMN. Validation of the Turkish
version of the Brief Pain Inventory in surgery patients.
2009;10(2):107-113. e102.
25. Cleeland C, Ryan KJA, Academy of Medicine, Singapore. Pain
assessment: global use of the Brief Pain Inventory. 1994.
26. Brady MJ, Cella DF, Mo F, et al. Reliability and validity of the
Functional Assessment of Cancer Therapy-Breast quality-of-life
instrument. 1997;15(3):974-986.
27. Aydemir OJTPD. Hastane anksiyete ve depresyon olcegi Turkce formunun
gecerlilik ve guvenilirligi. 1997;8:187-280.
28. Presant CA, Bosserman L, Young T, et al. Aromatase
inhibitor–associated arthralgia and/or bone pain: frequency and
characterization in non–clinical trial patients. Clinical breast
cancer. 2007;7(10):775-778.
29. Laroche F, Coste J, Medkour T, et al. Classification of and risk
factors for estrogen deprivation pain syndromes related to aromatase
inhibitor treatments in women with breast cancer: a prospective
multicenter cohort study. The Journal of Pain.2014;15(3):293-303.
30. Yang GS, Kim HJ, Griffith KA, Zhu S, Dorsey SG, Renn CL.
Interventions for the Treatment of Aromatase Inhibitor–Associated
Arthralgia in Breast Cancer Survivors: A Systematic Review and
Meta-analysis. Cancer nursing. 2017;40(4):E26-E41.
31. DeNysschen C, Burton H, Ademuyiwa F, Levine E, Tetewsky S, O’connor
T. Exercise intervention in breast cancer patients with aromatase
inhibitor‐associated arthralgia: a pilot study. European journal
of cancer care. 2014;23(4):493-501.
32. Irwin ML, Cartmel B, Gross CP, et al. Randomized exercise trial of
aromatase inhibitor-induced arthralgia in breast cancer survivors.J Clin Oncol. 2015;33(10):1104-1111.
33. Paulo TR, Rossi FE, Viezel J, et al. The impact of an exercise
program on quality of life in older breast cancer survivors undergoing
aromatase inhibitor therapy: a randomized controlled trial. Health
and Quality of Life Outcomes. 2019;17(1):17.
34. Fields J, Richardson A, Hopkinson J, Fenlon D. Nordic walking as an
exercise intervention to reduce pain in women with aromatase
inhibitor–associated arthralgia: a feasibility study. Journal of
pain and symptom management. 2016;52(4):548-559.
35. Galantino ML, Callens ML, Cardena GJ, Piela NL, Mao JJ. Tai Chi for
Well-being of Breast Cancer Survivors With Aromatase
Inhibitor-associated Arthralgias: A Feasibility Study. Alternative
Therapies in Health & Medicine. 2013;19(6).
36. Greenlee H, DuPont‐Reyes MJ, Balneaves LG, et al. Clinical practice
guidelines on the evidence‐based use of integrative therapies during and
after breast cancer treatment. CA: a cancer journal for
clinicians. 2017;67(3):194-232.
37. Lyman GH, Greenlee H, Bohlke K, et al. Integrative therapies during
and after breast cancer treatment: ASCO endorsement of the SIO clinical
practice guideline. Journal of Clinical Oncology.2018;36(25):2647-2655.
38. Gerritsen JK, Vincent AJ. Exercise improves quality of life in
patients with cancer: a systematic review and meta-analysis of
randomised controlled trials. British Journal of Sports Medicine.2016;50(13):796-803.
39. Shobeiri F, Masoumi SZ, Nikravesh A, Moghadam RH, Karami M. The
impact of aerobic exercise on quality of life in women with breast
cancer: a randomized controlled trial. Journal of research in
health sciences. 2016;16(3):127.
40. Zhang X, Li Y, Liu D. Effects of exercise on the quality of life in
breast cancer patients: a systematic review of randomized controlled
trials. Supportive Care in Cancer. 2019;27(1):9-21.
41. Cadmus LA, Salovey P, Yu H, Chung G, Kasl S, Irwin ML. Exercise and
quality of life during and after treatment for breast cancer: results of
two randomized controlled trials. Psycho‐Oncology: Journal of the
Psychological, Social and Behavioral Dimensions of Cancer.2009;18(4):343-352.